Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/5/2024 | $12.00 | Perform → Outperform | Oppenheimer |
9/25/2023 | $19.00 | Buy | H.C. Wainwright |
4/17/2023 | $14.00 → $13.00 | Strong Buy → Outperform | Raymond James |
10/15/2021 | $28.00 → $37.00 | Hold → Buy | Canaccord Genuity |
8/20/2021 | Perform | Oppenheimer | |
7/14/2021 | $24.00 → $28.00 | Hold | Canaccord Genuity |
7/9/2021 | $27.00 → $32.00 | Strong Buy | Raymond James |
Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00
H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00
Raymond James downgraded AngioDynamics from Strong Buy to Outperform and set a new price target of $13.00 from $14.00 previously
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $73.0 million 9.2% Med Tech Net Sales $31.5 million 25.0% Med Device Net Sales $41.5 million (0.4)% GAAP Gross margin of 54.8% GAAP loss pe
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual NanoKnife System Event Date: Wednesday, January 8, 2025 Time: 9:30am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-85
Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thro
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $73.0 million 9.2% Med Tech Net Sales $31.5 million 25.0% Med Device Net Sales $41.5 million (0.4)% GAAP Gross margin of 54.8% GAAP loss pe
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT on Thursday, January 16, 2025. A live webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event.
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
3 - ANGIODYNAMICS INC (0001275187) (Issuer)
SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)